Current information on cardiovascular risk (CVR) in HIV-infected patients in Spain is limited.
An analysis was made of a prospective multicentre cohort of Spanish HIV-infected patients (CoRIS) between January-2010 and July-2011. CVR was evaluated using Framingham, REGICOR and SCORE equations.
The study included 1019 patients (76 % males, mean age 40 years) recruited from 13 hospitals belonging to 10 autonomous communities in Spain. Almost two-thirds (65.4 % ) of patients were on antiretroviral therapy (ART), 36.7 % with non-nucleoside analogs, 24 % with protease inhibitors (PIs) (52 % with atazanavir/r or darunavir/r) and 4,6 % with raltegravir. More than half (56.2 % ) of the patients had an HIV viral load <50 copies/ml. Smoking prevalence was 46 % , HDL cholesterol (HDL-C) <40 mg/dl 36.1 % , total cholesterol (total-C) >200 mg/dl 27.8 % , age >45years 27.2 % , metabolic syndrome 11.5 % , hypertension 9.4 % , cocaine use 7 % , and diabetes 2.9 % . ART was associated with higher total-C and LDL-C concentrations, although also higher HDL-C and lower total-C/HDL-C ratio; patients receiving PIs boosted with a high ritonavir dose showed higher total-C levels and higher total-C/HDL-C ratio. According to Framingham cardiovascular, and coronary, REGICOR, and SCORE equations, 15.2 % , 6.4 % , 4.2 % and 3.9 % of patients, respectively, were classified as having moderate or high CVR.
In HIV-infected patients from CoRIS, prevalence of modifiable CVR factors is still high. Commonly used scores identify a relatively low number of patients with high CVR.